CARD14相关丘疹鳞屑性皮疹:包含银屑病与毛发红糠疹特征的谱系
研究描述了15个CARD14突变家系的丘疹鳞屑性皮疹,特征包括发病年龄早、面颊下巴耳朵明显受累、银屑病或毛发红糠疹家族史、对常规外用和系统性银屑病治疗反应差、乌司奴单抗治疗改善。作者提出CARD14相关丘疹鳞屑性皮疹(CAPE)这一术语,认为有CAPE临床特征者应进行CARD14测序,可能从乌司奴单抗治疗中获益。
要点
- CARD14相关丘疹鳞屑性皮疹(CAPE)特征包括发病年龄早、面颊下巴耳朵明显受累。
- CAPE常有银屑病或毛发红糠疹家族史,对常规外用和系统性银屑病治疗反应差。
- 乌司奴单抗治疗可改善CAPE,有CAPE临床特征者应行CARD14测序。
核心结论
- 许多CARD14突变者同时表现银屑病和毛发红糠疹特征,作者提出CARD14相关丘疹鳞屑性皮疹(CAPE)描述该疾病谱。
- 作者认为有CAPE临床特征者应进行CARD14测序,并可能从乌司奴单抗治疗中获益。
研究设计与样本
- 研究对象为因遗传性角化障碍登记处转诊进行基因检测的个体,从血液或唾液提取DNA,行多重靶向测序或全外显子测序,并回顾CARD14突变者的临床病史。
- 研究识别了15个CARD14相关丘疹鳞屑性皮疹(CAPE)家系。
主要发现
- CAPE特征包括发病年龄早、面颊下巴耳朵明显受累、银屑病或毛发红糠疹家族史。
- CAPE对常规外用和系统性银屑病治疗反应差,乌司奴单抗治疗可改善。
- 许多CARD14突变者同时表现银屑病和毛发红糠疹特征,可导致诊断不确定性。
- 这些皮疹常对甲氨蝶呤、口服维A酸类和肿瘤坏死因子-α抑制剂等常规银屑病治疗抵抗。
临床怎么用
- 作者认为有CAPE临床特征者应进行CARD14测序,并可能从乌司奴单抗治疗中获益。
局限性
- 样本量相对较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heterozygous mutations in caspase recruitment domain family member 14 gene (CARD14) have been shown to be associated with psoriasis and familial pityriasis rubra pilaris (PRP). Many subjects with CARD14 mutations display features of both disorders, which can result in diagnostic uncertainty. In addition, these eruptions are often recalcitrant to conventional psoriasis therapies such as methotrexate, oral retinoids, and tumor necrosis factor-α inhibitors. OBJECTIVE: We sought to describe the clinical characteristics, family history, and response to therapy in subjects with papulosquamous eruptions due to mutations in CARD14. METHODS: Subjects were referred for genetic testing as part of a registry of subjects with inherited disorders of keratinization. DNA was isolated from blood or saliva, and multiplex targeted sequencing or whole exome sequencing was performed. Clinical histories of subjects with CARD14 mutations were reviewed. RESULTS: We identified 15 kindreds with CARD14-associated papulosquamous eruption (CAPE). Characteristic features of CAPE include early age of onset; prominent involvement of the cheeks, chin, and ears; family history of psoriasis or PRP; minimal response to conventional topical and systemic psoriasis therapies; and improvement with ustekinumab. LIMITATIONS: Relatively small sample size. CONCLUSIONS: Many subjects with CARD14 mutations display characteristics of both psoriasis and PRP. We propose the term CARD14-associated papulosquamous eruption to describe this spectrum of disease. Subjects with clinical features suggestive of CAPE should undergo CARD14 sequencing and may benefit from treatment with ustekinumab.
引用
- Craiglow BG, Boyden LM, Hu R, et al. CARD14-associated papulosquamous eruption: A spectrum including features of psoriasis and pityriasis rubra pilaris. J Am Acad Dermatol. 2018. PMID: 29477734. doi:10.1016/j.jaad.2018.02.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。